Skip to content

Axogen AXGN Indefinite- lived intangible impairment

Indefinite- lived intangible impairment at other companies

Baxter International logo
Baxter InternationalBAX

Other financials

Income statement

See full
Revenue$61.5M+26.6%
Gross profit$46.2M+32.2%
Operating income-$2.8M-70.5%
Net income-$19.6M-411%
EPS (diluted)-$0.38-375%

Balance sheet

See full
Cash & equivalents$84.7M+251%
Total debt$20.6M-69.8%
Total equity$244.8M+132%
Total assets$289.5M+47.6%

Cash flow

See full
Operating cash flow$1.6M+112%
CapEx$2.8M+989%
Free cash flow-$1.2M+90.9%

Valuation

See full
Market cap$2.26B+110%
Enterprise value$2.2B+91.4%
P/S9.5×+4.0×

Profitability

See full
Gross margin75%+0.8pp
Operating margin-3.8%
Net margin-13.2%-22.8pp
FCF margin-12.9%-3.8pp

Returns & leverage

See full
Return on equity-18%-70.5pp
Debt / equity0.1×-0.6×
Current ratio7.1×+2.8×

Where this comes from

Reported directly by Axogen in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsGrossExcludingGoodwill.

The official record: Axogen’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axogen's indefinite- lived intangible impairment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axogen's indefinite- lived intangible impairment?
Axogen (AXGN) reported indefinite- lived intangible impairment of $8.79M in Q1 2026.
How has Axogen's indefinite- lived intangible impairment changed year-over-year?
Axogen's indefinite- lived intangible impairment increased by 25.2% year-over-year, from $7.02M to $8.79M.
What is the long-term trend for Axogen's indefinite- lived intangible impairment?
Over 5 years (2020 to 2025), Axogen's indefinite- lived intangible impairment has grown at a 22.7% compound annual growth rate (CAGR), from $2.94M to $8.17M.